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Purpose of review: The skin is home to a diverse milieu of bacteria, fungi, viruses, 14 
bacteriophages and archaeal communities. The application of culture independent approaches 15 
has revolutionized the characterization of the skin microbiome and have revealed a 16 
previously under-appreciated phylogenetic and functional granularity of skin-associated 17 
microbes in both health and disease states.   18 
Recent findings: The physiology of a given skin niche drives the site-specific differences in 19 
bacterial phyla composition of healthy skin. Changes in the skin microbiome have 20 
consistently been associated with atopic dermatitis (AD). In particular, Staphylococcus 21 
aureus overgrowth with concomitant decline in S. epidermidis is a general feature associated 22 
with AD and is not restricted to eczematous lesions. Changes in fungal species are now also 23 
being described. Changes in the composition and metabolic activity of the gut microbiota are 24 
associated with skin health. 25 
Summary: We are now beginning to appreciate the intimate and intricate interactions between 26 
microbes and skin health. Multiple studies are currently focussed on the manipulation of the 27 
skin or gut microbiome to explore their therapeutic potential in the prevention and treatment 28 
of skin inflammation.  29 
 30 




An enormous variety of microbes colonize all internal and external body surfaces. 33 
These microbes are organized within complex community structures, utilizing nutrients from 34 
other microbes, host secretions and the diet. The microbiome is defined as the sum of these 35 
microbes, their genomic elements and interactions in a given ecological niche. In addition to 36 
bacteria, fungi, viruses and bacteriophages are also considered to be important components of 37 
the microbiome. The composition and metabolism of the microbiome is dependent on the 38 
specific body site examined, resulting in a series of unique habitats within and between 39 
individuals that can change substantially over time [1]. This presents significant challenges to 40 
the local immune system, which should tolerate the presence of these microbes to avoid 41 
damaging host tissue while retaining the ability to respond appropriately to invasive 42 
pathogens. The mechanisms that mediate host-microbe communication are highly 43 
sophisticated and need to be constantly coordinated [2]. Indeed, disrupted communication 44 
between the microbiome and the host due to altered microbiome composition and/or 45 
metabolism is thought to negatively influence immune homeostatic networks and may play a 46 
role in immune hypersensitivity to environmental exposures, such as allergens [3, 4, 5]. 47 
Relatively recently, epidemiological studies have identified associations between the 48 
migration from traditional farming to urban environments, changes in dietary practices, lack 49 
of contact with animals, use of antibiotics, lifestyle factors and reduced exposure to 50 
biodiverse environments with changes in the composition of the human microbiome and the 51 
increased incidence of allergic, inflammatory, metabolic and neuropsychiatric disorders [6*, 52 
7*, 8*, 9*, 10*, 11*]. In particular, early life events have been shown to be significant 53 
modifiers of microbial establishment, colonization, development and maturation. These 54 
include mode of delivery, breastfeeding, mother’s diet and health status, antibiotics and other 55 
drug usage in pregnancy and early childhood, early-life environment (i.e. number of siblings, 56 
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pets at home, proximity to farm animals and green areas) [12*, 13, 14*, 15*, 16*, 17, 18]. In 57 
this review, we will highlight some of the recent advances in our knowledge regarding the 58 
influence of the microbiome on skin biology, skin immune reactivity and skin diseases such 59 
as atopic dermatitis (AD). In addition, we will discuss the potential translation and challenges 60 
associated with microbial-based therapies for the skin. 61 
 62 
Skin as a Unique Microbial Habitat 63 
The skin is the most exposed organ, serving as an interface shielding 64 
underlying structures against external aggressions. Though open to colonization from the 65 
environment, human skin serves as a strong selective filter, largely unsuitable for most 66 
microbes to permanently reside [19]. At the forefront is the highly keratinized epidermis, the 67 
result of a specialized differentiation process of keratinocytes (the main cell type in the 68 
epidermal barrier) interspersed between intercellular lipids, a collection of ceramides, 69 
cholesterol and various fatty acids. Recent studies have shown that the uppermost layer of the 70 
epidermis, the stratum corneum (SC), harbours a rich diversity of microbes [20*] contributing 71 
to the barrier properties of the skin. An aqueous and lipid layer, which is present above the 72 
epidermis, also contribute to the ecology of the surface. Below the epidermis are several 73 
layers that form part of the skin barrier, profoundly affecting function and also harbouring 74 
microbes [21].   A growing body of data suggests that cutaneous microbes can influence the 75 
structure and function of healthy skin without penetrating the epidermis [22]. Contributing to 76 
the microenvironment is the presence and function of additional skin appendages, including 77 
sweat glands, hair follicles, sebaceous glands and the dermal layers which in turn drives the 78 
site-specific differences in bacterial phyla composition of healthy skin [21, 23, 24]. Eccrine 79 
sweat (water, salt and electrolytes) is secreted directly onto the skin surface, which works to 80 
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acidify the skin, creating an environment that plays a major role in limiting the composition 81 
of microbes that can survive and proliferate.  82 
Propionibacteria, Corynebacteria and Staphylococci make up the most abundant 83 
bacteria species on the skin. Staphylococcal species are found in moist skin niches, and are 84 
halotolerant organisms that have evolved to use urea found in sweat as a nitrogen source. 85 
Certain Staphylococcus species, e.g. S. aureus, are able to produce adherens that promote 86 
bacterial adherence to skin and produce proteases that release nutrients from the SC [25**].  87 
These sweat glands constitutively express several antimicrobial peptides (AMPs), including 88 
cathelicidin and β-defensins. The density of eccrine sweat glands impacts the microbial 89 
colonization of the skin [26]. Sebaceous glands are connected to hair follicles, forming the 90 
pilosebaceous unit. Sebaceous glands secrete lipid-rich sebum, which lubricates the hair and 91 
skin. The breakdown of sebum generates free fatty acids, which work to control microbial 92 
colonization, along with sebocyte-derived cathelicidin, β-defensins and antimicrobial 93 
histones. However, organisms such as Propionibacteria acnes, a facultative anaerobe, are 94 
able to flourish in the anoxic sebaceous gland as they can produce proteases and lipases that 95 
release amino acids and free fatty acids (that favors bacterial adherence) from skin and sebum 96 
respectively and cause acne vulgaris following their over proliferation in this lipid rich 97 
environment [25**]. Corynebacterium has adapted to survive in moist sites by utilizing SC 98 
and sebaceous lipids to generate breakdown products to coats its cell surface. 99 
 Current microbial detection techniques have shown that bacteria are not only present 100 
on the skin surface but are also found in deeper layers of the epidermis, and even in the 101 
dermis and dermal adipose tissue.  Recent studies have helped define the skin microbiome 102 
landscape, indicating that the skin harbours a diverse population of microbes whose 103 
composition is largely determined by site specific physiological factors, such as moisture and 104 




Healthy Skin Microbiome 107 
The development and application of culture independent approaches (such as 108 
metagenome shotgun sequencing) have revolutionized the characterization of the skin 109 
microbiome and have revealed a previously under-appreciated phylogenetic and functional 110 
granularity of skin-associated microbes in both health and disease states. Despite the harsh 111 
nutrient-poor landscape, healthy human skin is home to a heterogeneous milieu of 112 
commensal microorganisms including bacteria, fungi, viruses, bacteriophages and archaeal 113 
communities [27]. Multiple factors such as age, gender, ethnicity, climate, UV exposure and 114 
lifestyle shape the composition of the healthy skin microbiome. It has also been observed that 115 
the adult skin microbiome can remain stable over a period of at least 2 years irrespective of 116 
environmental changes [28]. The initial colonization of the newborn baby however depends 117 
on many factors, including the delivery mode. With vaginal delivery there is acquisition of 118 
maternal vaginal bacterial flora, and with caesarean section acquisition of skin-associated 119 
microorganisms. Postnatally, the immature immune system allows microbial colonization in 120 
the absence of inflammatory responses. This tolerogenic environment can be attributed to the 121 
infiltration of neonatal skin by regulatory T cells. Thereafter different commensals educate 122 
distinct aspects of the host immune system in order to respond appropriately to future 123 
exposure to pathogens. During puberty, the skin microbiome composition shifts in favor of 124 
lipophilic skin organisms [29, 30]. The continuous molecular cross-talk between cutaneous 125 
epithelia, tissue resident innate and adaptive immune cells and skin-associated microbes 126 
allows the establishment of commensal partners, which have essential roles in protection 127 
from invasive pathogens, educating distinct aspects of the host immune system to respond 128 
appropriately to future exposure to pathogens, the breakdown of skin-derived lipids and 129 
metabolites, and maintenance of immune homeostatic networks [25**]. Interactions between 130 
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skin microorganisms may be synergistic or competitive. These interactions may be exploited 131 
to identify mechanisms by which commensal microorganisms mediate direct and indirect 132 
colonization resistance in the skin.  133 
Whilst skin bacterial microorganisms are the most abundant at the kingdom level, 134 
fungi are the least abundant. Within the skin mycobiome, lipophilic Malassezia species 135 
represent the most predominant fungal flora on the human skin. They are unable to synthesize 136 
their own nutrients and therefore produce lipid-utilizing enzymes in order to exploit the lipid-137 
rich environment of the skin. Currently, there are relatively few skin-associated fungal 138 
sequenced reference genomes available, which will need to be improved to facilitate future 139 
mechanistic assessments on the skin mycobiome. Little is currently known concerning the 140 
spectrum of viral and bacteriophage communities present on healthy skin or their interactions 141 
with the microbiome and host cells but may be of significant relevance to conditions such as 142 
AD complicated by eczema herpeticum and skin cancers associated with oncoviruses.  143 
 144 
Microbiome Associated with Skin Disorders 145 
Understanding site-specific differences in microbial composition advances our 146 
understanding of diseases such as AD, psoriasis and acne vulgaris. The association between 147 
AD and an altered skin microbiome is now well documented. S. aureus overgrowth is a 148 
common feature of AD and is not restricted to eczematous lesions [31*]. S. aureus 149 
colonization is evident in 90% of AD cases, associates with AD severity and increased 150 
allergen sensitization. AD associated defects in stratum corneum integrity, decreased 151 
expression of structural proteins, altered skin lipid composition and skin pH and aberrant 152 
cutaneous and systemic immune responses facilitate S. aureus overgrowth, whilst S. aureus-153 
derived proteases and toxins further damage the skin barrier and induce innate and adaptive 154 
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immune responses [32**]. It has also been observed that the S. aureus overgrowth is 155 
associated with a depletion in commensal Staphylococci such as S. epidermidis, and other 156 
skin commensal taxa including Propionibacterium, Streptococcus, Acinetobacter, 157 
Corynebacterium, Prevotella and Proteobacteria.  158 
While it still needs to be clarified whether S. aureus contributes to the initiation of AD 159 
or if S. aureus blooms as a consequence of the disease, a number of studies do 160 
mechanistically link S. aureus with skin inflammation. S. aureus -toxin induces the 161 
degranulation of mast cells, which promotes innate and adaptive immune responses [33]. S. 162 
aureus -toxin can also induce IL-1 production from monocytes, which may promote Th17 163 
responses, or IL-17 production from CD4+ T cells [34]. Through the defective skin barrier, S. 164 
aureus may reach the dermis where it interacts with immune cells and trigger cytokine 165 
production including IL-4, IL-13, IL-22 and TSLP [35]. The Th2 inflammatory milieu is 166 
further deleterious to the epidermal barrier and can additionally impair tissue production of 167 
antimicrobial peptides (AMPs) such as human beta defensins (hBD)-2, hBD-3 and 168 
cathelicidin LL-37, thus impairing pathogen clearance.  169 
The role for fungi, such as Malassezia species, is increasingly being investigated in 170 
AD. Malassezia DNA has been detected in 90% of AD skin lesions and colonization 171 
increases with disease severity [36]. In addition, different Malassezia strains were found in 172 
AD and healthy individuals suggesting the existence of key pathogenic strains in AD [37]. It 173 
has been shown that Malassezia could contribute to AD pathogenesis by secreting 174 
immunogenic proteins that induce proinflammatory cytokines, upregulate expression of TLR-175 
2 and TLR-4 on keratinocytes, and induction of auto-reactive T cells [38]. Most recently, it 176 
was reported that Malassezia-induced Th17 responses are required for antifungal immunity 177 
within the skin but might also promote skin inflammation [39**]. 178 
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 S. aureus, via its promotion of Th17 polarising responses, has also been shown to be 179 
relevant to psoriasis lesions [40*]. In addition, increased abundance of Brevibacterium and 180 
Kocuria palustris and Gordonia, were associated with psoriatic lesions on the back and the 181 
elbow, respectively. In the same study, a significantly higher abundance of Malassezia 182 
restricta was detected on the back, while Malassezia sympodialis dominated the elbow 183 
mycobiota. In psoriatic elbow skin, there was a significant correlation between the occurrence 184 
of Kocuria, Lactobacillus, and Streptococcus with Saccharomyces, which was not observed 185 
in healthy skin [41*]. Interestingly, successful treatment with balneotherapy or UVB was 186 
associated with a significant change in the lesion-associated microbiome [42, 43*]. 187 
 188 
Role of Gut Microbes in Skin Disorders 189 
Early studies demonstrated that patients with AD have lower levels of 190 
Bifidobacterium in the gut compared to healthy controls and Bifidobacterium levels were 191 
inversely correlated with AD disease severity [44]. Several studies have since shown that 192 
alterations in gut microbiota composition can precede the development of AD. Early gut 193 
colonisation with C. difficile was associated with AD development and low gut microbiota 194 
diversity and specifically low Bacteriodetes diversity at 1 month was associated with AD 195 
development at 2 years of age [36, 45]. Reduced colonization of mucin-degrading bacteria 196 
(Akkermansia muciniphila, Ruminococcus gnavus and Lachnospiraceae) were more recently 197 
shown for AD patients, which were associated with alterations in immune development in the 198 
AD group compared with the control group [46**]. In addition to modifying the host gut 199 
immune system, certain metabolites produced by microbes within the gut can be absorbed 200 
and thereby may directly influence the skin. For example, children with the highest levels of 201 
faecal short-chain fatty acids such as butyrate at 1 year of age, have a lower risk of 202 
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developing AD by 6 years of age [47*]. Differences in gut taxa and overall gut microbial 203 
diversity has also been noted for patients with psoriasis [48*]. 204 
 205 
Therapeutic Potential of the Microbiome 206 
Multiple studies are currently focussed on the manipulation of the skin microbiome to 207 
explore its therapeutic potential. Transplant of S. hominis and S. epidermidis strains that 208 
secrete antimicrobial peptides was effective in controlling S. aureus overgrowth [49]. More 209 
recently, emollients supplemented with a Vitreoscilla filiformis lysate or topical 210 
administration of Rosemonas mucosa improved clinical severity scores in adults and children 211 
with AD [50**].  212 
In addition to topical bacterial treatments, oral administration of probiotics has also 213 
been examined. Prenatal and post-natal treatment with certain Lactobacillus and 214 
Bifidobacterium strains can reduce risk of AD development in infants, while a mixture of 215 
probiotic strains was recently shown to reduce SCORAD index and topical steroid use in 216 
children with AD [51*, 52*]. These beneficial effects in the skin may be associated with 217 
changes in T cell-mediated responses [53, 54]. Little has been reported on the clinical effects 218 
of probiotic treatment in patients with psoriasis, but administration of a B. longum strain to 219 
adults with psoriasis resulted in reduced circulating levels of CRP, TNF and IL-17 [55]. 220 
Taken together, supplementation with specific probiotic strains may modulate the gut 221 
microbiota in a way that attenuates inflammation within the skin.  222 
 223 
Conclusions 224 
We are now beginning to appreciate the intimate and intricate interactions between 225 
microbes and skin health. Changes in the skin microbiome are associated with damaged or 226 
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inflamed skin, but the exact pathological mechanisms or their therapeutic potential remain 227 
largely unknown. Indeed, the role of gut microbes in skin health is a fascinating area of study 228 
and reaffirms the existence of a gut-skin axis. In the near future, we expect that analysis of 229 
the skin microbiome will assist in the clinical management of skin disorders, including the 230 
better identification of disease-related microbial communities or “Dermatypes”, akin to 231 
recently described gut enterotypes. It will afford us the possibility of identifying novel 232 
treatment modalities and appropriate microbial reconstitution strategies. However, we still 233 
need to better understand the influence of host physiological changes and environmental 234 
challenges on the microbiota, describe the nonbacterial members of the skin microbiome, 235 
improve the resolution of our assessments to allow strain-level discrimination and most 236 
importantly we need better models to elucidate the functional properties of the skin 237 
microbiome. 238 
 239 
Key points:  240 
 The microenvironment and physiology of a given skin niche drives the site-specific 241 
differences in microbiome composition. 242 
 S. aureus is consistently associated with atopic dermatitis 243 
 Gut microbes, and their metabolites, influence skin health 244 
 Identification of skin microbiome community patterns, or Dermatypes, will assist in 245 
patient stratification 246 
 Microbial reconstitution of the skin community may have significant therapeutic 247 
benefits 248 
 249 
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